Razvoj, validacija i procjena ekološke prihvatljivosti analitičke metode za određivanje sadržaja etrasimoda

master's thesis

• Title (english): Development, validation and assessment of environmental acceptability of an analytical method for the determination of etrasimod content
• Author: Vanja Cesarec
• Mentor: Ana Mornar Turk (mentor)
• Committee member: Ana Mornar Turk (predsjednik povjerenstva)
• Committee member: Laura Nižić Nodilo (član povjerenstva)
• Committee member: Dinko Šoić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmaceutical analysis); Zagreb
• Defense date and country: 2023-06-29, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Osobine upalnih crijevnih bolesti (engl. Inflammatory bowel disease, IBD) jesu da su to kronične
bolesti nepredvidivog tijeka čija incidencija sve više raste. Glavni oblici bolesti su ulcerozni kolitis
i Crohnova bolest koje se razlikuju po lokaciji i prirodi bolesti. Etrasimod je oralni, sfingozin-1-
fosfat receptor modulator koji se trenutno ispituje kao novo terapijsko rješenje u liječenju upalnih
bolesti crijeva, prvenstveno ulceroznog kolitisa. Modulacija sfingozin-1-fosfat receptora (S1P)
ispituje kao potencijalni terapijski put u liječenju različitih imunosnih bolesti. U ovom radu
predložena je analitička metoda za određivanje etrasimoda primjenom tekućinske kromatografije
visoke djelotvornosti. Metoda je validirana sukladno ICH smjernicama te je utvrđeno da je metoda
selektivna, linearna, osjetljiva, precizna i točna. Primjenom računale platforme AGREE procijenjena
je ekološka prihvatljivost predložene metode te je utvrđeno kako je metoda zadovoljava načela
zelene analitičke kemije.

Abstract (english)

Inflammatory bowel disease (IBD) is term for the group of diseases discribed as chronic and
unpredictable with increasing incidence. Main forms of the disease are Ulcerative colitis and
Crohne's disease, which differ by the location and nature of the disease. Etrasimod is oral,
sphigosine-1-phosphate receptor modulator that is currently being reserched as new therapeutic
option in treating inflammatory bowel diseases, primarily for treating ulcerative colitis. Modulation
of sphigosine-1-phosphate (S1P) receptors is researched as potencial therapeutic target in treating
various immune diseases. In this thesis chosen method for the determination of etrasimod is High
performance liquid chromatography. Method has been validated following the ICH guidelines and
it is confirmed that the method is selective, linear, sensitive, precise and accurate Analitical
GREEnness calculator has been used for evaluation of greenness of chosen analitical method and
final result has shown that method meets the 12 priciples of green analitical chemistry.

• Keywords: Etrasimod; ulcerozni kolitis; HPLC; validacija; AGREE kalkulator
• Keywords (english): Etrasimod; ulcerative colitis; HPLC; validation; AGREE calculator
• Language: croatian
• URN:NBN: urn:nbn:hr:163:518516
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Embargoed access; Embargo expiration date: 2025-06-29
• Created on: 2023-12-01 11:40:57